Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLORENZA dose optimization study of mirvetuximab soravtansine combinations in ovarian cancer
2025-521606-18-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of mirvetuximab soravtansine in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Treatment-emergent adverse events, TEAEs leading to discontinuation and 3 more. Planned start Jan 2026; status: authorised.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2025-521606-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521606-18-00.